Abstract
Peripheral T-cell lymphoma (PTCL) is an aggressive lymphoma that accounts for less than 10% of all lymphomas in adults. Although the 5-year overall survival (OS) rate of ALK+ anaplastic large cell lymphoma (ALCL) is around 70%, those of other types of PTCL (ALK- ALCL, angioimmunoblastic T cell lymphoma [AITL] and PTCL not otherwise specified [PTCL(NOS)]) is only 30 to 40% and that of adult T cell leukemia/lymphoma is less than 30% Therefore, a new targeted therapy for PTCL is mandatory. Since 2011, forodesine, romidepsin, pralatrexate, mogamulizumab and other new drugs have been introduced for the treatment of relapsed PTCL, but improved prognosis of PTCL has not been definitely demonstrated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
